Allogeneic approach unlocks CAR T cell benefits in solid tumors.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 39920392.
- Also identified by DOI 10.1038/s41591-025-03510-3 and PMC identifier 12365085.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A small but in-depth study of allogeneic CAR T cell therapy in patients with high-risk neuroblastoma shows feasibility and potential efficacy, and mechanistic insights reveal pathways to improved functionality of CAR T cells in solid tumors.